Genscript Biotech Dirección

Dirección controles de criterios 2/4

El CEO de Genscript Biotech's es Weihui Shao, nombrado en Jul 2021, tiene una permanencia de 2.75 años. posee directamente un 0.021% de las acciones de la empresa, con un valor de €574.94K. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 7 años, respectivamente.

Información clave

Weihui Shao

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.8yrs
Participación del CEO	0.02%
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	7.1yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Weihui Shao (43 yo)

2.8yrs

Permanencia

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jiange Meng	Executive Chairman	8.8yrs	US$1.07m	0.013% $ 419.2k
Weihui Shao	CEO & COO	2.8yrs	sin datos	0.021% $ 669.8k
Ye Wang	Co-Founder	22.3yrs	US$615.00k	0.037% $ 1.2m
Shiniu Wei	Chief Financial Officer	3.4yrs	sin datos	sin datos
Fangliang Zhang	co-founder & Executive Director	1.4yrs	US$271.00k	sin datos
Li Zhu	Chief Strategy Officer & Executive Director	3.5yrs	US$529.00k	0.058% $ 1.8m
Wai Ling Wong	Company Secretary	8.8yrs	sin datos	sin datos

3.5yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de G51 se considera experimentado (3.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jiange Meng	Executive Chairman	8.8yrs	US$1.07m	0.013% $ 419.2k
Ye Wang	Co-Founder	9yrs	US$615.00k	0.037% $ 1.2m
Fangliang Zhang	co-founder & Executive Director	2yrs	US$271.00k	sin datos
Li Zhu	Chief Strategy Officer & Executive Director	3.5yrs	US$529.00k	0.058% $ 1.8m
George Church	Member of Advisory Board	4.7yrs	sin datos	sin datos
Yuexin Pan	Non-Executive Director	8.8yrs	US$64.00k	0.0027% $ 84.0k
Hong Xin Guo	Independent Non-Executive Director	8.8yrs	US$95.00k	0.0029% $ 92.0k
Zumian Dai	Independent Non-Executive Director	8.8yrs	US$105.00k	sin datos
Xuehai Wang	Independent Non-Executive Director	3.5yrs	US$120.00k	sin datos
Luquan Wang	Non-Executive Director	9yrs	sin datos	0.030% $ 952.6k
Jiuan Pan	Independent Non-Executive Director	5.5yrs	US$124.00k	sin datos
Jiafen Wang	Non-Executive Director	5.5yrs	US$51.00k	0.00019% $ 6.0k

7.1yrs

Permanencia media

56.5yo

Promedio de edad

Junta con experiencia: La junta directiva de G51 se considera experimentada (7 años de antigüedad promedio).

Genscript Biotech Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Insider recently sold €159k worth of stock

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Recent updates

Now 22% undervalued after recent price drop

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 22% undervalued after recent price drop

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

New major risk - Share price stability

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

New minor risk - Share price stability

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold €159k worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Now 20% undervalued

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold €246k worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold €988k worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: €1.40

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: €1.06

New 90-day low: €1.08

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: €1.25

Co-Founder recently bought €410k worth of stock

First half earnings released

New 90-day low: €1.28

First half earnings released

New 90-day low - €1.60

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

New 90-day low - €1.66

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad